Scientists Turn Tobacco Into Psychedelic Medicine Factory

Scientists just turned ordinary tobacco plants into natural factories for producing five different psychedelic compounds that show promise for treating mental health conditions.

Researchers at Israel's Weizmann Institute of Science added specific genes to tobacco plants, teaching them to make DMT, psilocybin, psilocin, bufotenine, and 5-methoxy-DMT. These are the same compounds found in magic mushrooms, certain plants used in traditional ceremonies, and even some toad species.

The team chose tobacco because it naturally produces high amounts of tryptophan, the amino acid building block needed to create these psychedelics. By identifying the right genes from DMT-containing plants like those used in ayahuasca brews, they successfully converted tobacco into a production system for therapeutic compounds.

This matters because traditional harvesting creates serious problems. Gathering psychedelics from wild mushrooms, plants, and animals threatens species already struggling with habitat loss. Lab synthesis works but requires multiple steps, special materials, and often produces unwanted byproducts.

The engineered plants offer a cleaner path forward. Some tobacco plants even produced all five compounds simultaneously, though they made smaller amounts of each compared to plants focused on just one psychedelic.

The Ripple Effect

Recent research suggests psychedelics could help treat severe depression, anxiety, and post-traumatic stress disorder. Indigenous communities have used these compounds medicinally and spiritually for thousands of years, but Western medicine is just beginning to explore their therapeutic potential.

Australia led the way in 2023, becoming the first country to approve psilocybin for treatment-resistant depression and MDMA for PTSD at a national level. As more countries consider similar approvals, scientists need reliable, sustainable sources for research and treatment.

The temporary gene insertion method also addresses safety concerns. Since the changes aren't permanent, the modified plants can't reproduce and spread psychedelic-producing genetics into the environment. This prevents misuse while enabling controlled production for medical research.

Plant geneticist Rupert Fray notes that about 25 percent of prescription drugs already come at least partially from plants. Creating "green factories" in controlled greenhouse settings could revolutionize how we produce needed medications.

The research team emphasized their goal was proving feasibility. Now industry experts can determine the best commercial approaches for producing these promising therapeutic compounds at scale.

This breakthrough opens doors for more accessible mental health research while protecting threatened species and our environment.